mRNA vaccine for melanoma reduces relapse after therapy, trial shows
NBCAPR 2 2023
This groundbreaking news out of the UK shows that mRNA technology can be used to prevent several types of deadly cancers. Scientists have gotten this far with very little funding, so imagine the benefits if they received a major boost in their funding to help move these treatments into the global medical market.
Questions surrounding the need for immense amounts of funding should prompt further questions about how people will afford these mRNA vaccines once they're on the market. According to sources close to the research, these trials have cost £400K ($500K) per patient. Cancer research is incredibly important, but so is making medicine affordable.